High prevalence of previous dengue virus infection among first-generation Surinamese immigrants in the Netherlands by unknown
RESEARCH ARTICLE Open Access
High prevalence of previous dengue virus
infection among first-generation Surinamese
immigrants in the Netherlands
Femke W Overbosch1,2*, Anneke van den Hoek1,3, Janke Schinkel4 and Gerard JB Sonder1,2,3
Abstract
Background: A substantial portion of Dutch travellers is comprised of immigrants returning to their country of
origin to visit friends and relatives (VFRs), including VFRs returning to dengue-endemic areas such as Suriname.
Limited attention has been focused on dengue among immigrants, therefore it is unknown whether immigration
has effect on the epidemiology of (severe) dengue among VFRs.
To get more insight in the seroprevalence of dengue among Surinamese immigrants, we conducted a
seroprevalence study on a convenience sample of first-generation Surinamese immigrants living in the Netherlands.
Methods: Blood samples were tested for IgG antibodies to DENV antigen serotypes (1, 2, 3 and 4). Gender, age,
years lived in Suriname before immigration, history of yellow fever vaccination, and time between yellow fever
vaccination and blood sample collection were examined as possible predictors for previous infection.
Results: Of the studied 400 Surinamese travellers with a mean age of 52 years (range 18–89), 37% were male.
Serology suggestive of past DENV infection was found in 325 individuals (81.3%; 95% CI: 77-85%). The time lived in
Suriname before immigration was the only significant predictor for previous DENV infection.
Conclusions: Most first-generation Surinamese immigrants have evidence of past DENV infection, probably
comparable to Surinamese inhabitants. Whether this influences the number of cases of (severe) dengue when
travelling requires more study.
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Background
Dengue is a mosquito-borne infection found in tropical
and sub-tropical regions. The spectrum of clinical manifesta-
tions of dengue varies from a mild febrile self-limiting illness
to a severe, potentially fatal disease. Substantial gaps remain
in the basic understanding of the pathogenesis. Known is
that there are four distinct, but closely related, serotypes
of the virus that cause dengue (DENV-1, -2, -3 and -4).
Recovery from infection by one serotype provides lifelong
immunity against that particular type [1]. Hypothesized
and strengthened by epidemiologic studies [2,3] is that
subsequent infection by other serotypes increases the risk
of developing “severe dengue” also known as Dengue
Haemorrhagic Fever.
In recent years, transmission in endemic areas has in-
creased, predominantly in urban and semi-urban settings,
and has become a major international public health con-
cern. The disease is now endemic in more than 100 coun-
tries in Africa, the Americas, the Eastern Mediterranean,
South East Asia and the Western Pacific, the latter two
being the most seriously affected. Over 2.5 billion people
(which is over 40% of the world’s population) are at risk
[1]. The WHO estimates there may be 50–100 million
dengue virus (DENV) infections worldwide every year.
An estimated 500,000 people with severe dengue require
hospitalisation each year, a large proportion of whom are
children. About 2.5% of those affected die [1].
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The Netherlands is not a dengue-endemic area; therefore
Dutch citizens are not at risk of contracting a DENV
infection in their home country. On the other hand,
Dutch travellers are at substantial risk for DENV infection
when travelling to endemic areas. A Dutch prospective
study among short-term travellers conducted in 2006–2007
showed a serology-based attack rate of 1.2% and an inci-
dence rate of 14.6 per 1000 person-months [4].
A substantial portion of Dutch travellers is comprised
of immigrants returning to their country of origin to visit
friends and relatives (VFRs), including VFRs returning to
dengue-endemic areas such as Suriname, a former Dutch
colony in the Caribbean (population 492,000 people) [5].
In 2010, 101,578 travellers from the Netherlands arrived
in Suriname [6].
Although previous reports investigated the seroprevalence
of dengue among people living in dengue endemic
areas, limited attention has been focused on dengue
among immigrants. Immigration to a non dengue endemic
area causes deviation of exposure to DENV among immi-
grants compared to inhabitants of dengue endemic areas.
Continuous exposure to DENV shifts to sporadic exposure
during visits to the country of origin, which probably
has consequences for the moment of encounter with a
secondary, and potentially more severe, DENV serotype
among immigrants. As far as we know, no research has
been performed on dengue seroprevalence rates among
Surinamese immigrants, nor among Surinamese nationals
in their home country. Taking into account that different
serotypes have been introduced in the Americas in past
decades [7] and that predominant DENV serotypes can
vary by year [8], immigration could influence the epidemi-
ology of (severe) dengue among Surinamese immigrants.
To get more insight in the seroprevelance among this
group of travellers, we conducted a seroprevalence study
among first-generation Surinamese immigrants living in
the Netherlands who sought travel health advice at the
Public Health Service’s Travel Clinic in Amsterdam.
Methods
Study population and design
A serum bank was used for this study, which consisted
of blood samples of Surinamese first-generation immi-
grants who attended the Public Health Service’s Travel
Clinic in Amsterdam from February 2008 to December
2011. These participants had been tested for immunity
against hepatitis A or hepatitis B. Inclusion criteria for
the hepatitis A and B immunity project were to have
been born before 1970 or 1989, respectively. Data were
collected concerning date of birth, gender, vaccination
record, country of origin of both the participant and par-
ents, and duration lived in country of origin. All partici-
pants had provided written informed consent to use the
remains of the blood sample for anonymous scientific
research on other infectious diseases. Following the rules
stated in the Medical Research Involving Human Subjects
Act (in Dutch: Wet Medisch-wetenschappelijk Onderzoek
[WMO]), the informed consent letters for the hepatitis A
and hepatitis B study were reviewed by the Medical Ethical
Committee of the Academic Center of Amsterdam. The
Medical Ethical Committee of the Academic Medical
Center of Amsterdam approved all documents of the
hepatitis A study (MEC 07/270), and reviewed all docu-
ments of the hepatitis B study and judged that evaluation
of the hepatitis B study was not required (MEC 09/014).
Therefore, we did not seek further waiver or approval for
this specific dengue virus study.
Laboratory
Blood samples were immediately stored at 6°C, then
centrifuged and frozen at −80°C within 24 hours after
collection. After being thawed they were tested for
total immunoglobulin (IgG) antibodies to DENV anti-
gen serotypes 1, 2, 3 and 4 by using an indirect ELISA
(Panbio Diagnostics, Brisbane, Queensland, Australia)
according to the manufacturer’s instructions. Test out-
comes for DENV IgG antibodies were expressed as signal-
to-cutoff ratios (s/co) and were interpreted according to the
manufacturer’s instructions: ratios <0.9 were considered
negative and thus as no evidence for past DENV infection,
ratios ≥ 1.2 were considered reactive and thus as evidence
for past DENV infection, and ratios 0.9-1.1 were considered
boundary values.
Statistical analysis
Test outcomes for DENV IgG antibodies which were
considered boundary values according to manufacturer’s
instructions, were allocated as negative for simplicity in
statistical analysis.
SPSS for windows version 19.0 was used to obtain preva-
lence, prevalence ratios and 95% confidence intervals, by
means of Poisson regression analysis with robust standard
errors [9]. All variables with an overall p-value < 0.1 in uni-
variate analysis were included in a multivariate analysis.
Results
The serum bank included 400 unique samples of
first-generation Surinamese immigrants living in the
Netherlands, who intended to travel to (sub-)tropical
countries. Eleven participants (2.8%) did not meet the age
inclusion criteria for the original study; 3 participants from
the hepatitis A project were born after 1970, and 8 partici-
pants from the hepatitis B project were born after 1989. We
did not exclude these participants in our analysis. The mean
age was 52 years (range 18–89) and 37% were male.
In 325 participants, DENV IgG was present, suggesting
past dengue virus infection, making the serologic results
suggestive of previous dengue virus infection in 325/400
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(81.3%; 95% CI: 77-85%) participants. Six participants
(1.5%) had DENV IgG levels at boundary values and there-
fore considered as negatives. Table 1 shows the prevalence
(Ps) and prevalence ratios (PRs) with univariate and multi-
variate 95% confidence intervals. In univariate analysis, the
prevalence in Surinamese > 60 years was significantly higher
than in Surinamese aged 40 years or younger and positively
related to the duration participants had lived in Suriname
before immigration. In multivariate analysis, only duration
of living in Suriname before immigration remained a
significant predictor for previous DENV infection. The
seroprevalence was not related to history of yellow fever
vaccination or time between yellow fever vaccination
and blood sample collection.
Discussion
In this study the prevalence of dengue virus IgG antibodies
among first-generation Surinamese immigrants was 81%.
Although seroprevalence studies among Surinamese
inhabitants are not available, this is comparable with the
results from seroprevalence studies among populations in
Latin America [10-13]. It seems like immigration to a non
dengue endemic country causes little difference in dengue
seroprevalence between the Surinamese immigrants and
the majority of populations living in dengue-endemic
areas of the Americas and the Caribbean get infected
with the dengue virus.
As expected, the seroprevalence of previous DENV
infection in our study was positively related to the duration
participants had lived in Suriname before immigration. This
is in line with studies performed among persons living in
dengue-endemic countries in Latin America where they
found higher seroprevalence rates of DENV antibodies by
increasing age, which can be seen as a marker for duration
of exposure [13,14].
A limitation of this study is that the used ELISA was not
DENV serotype specific, making the number of participants
at risk for a secondary infection with a different serotype
Table 1 Characteristics of 400 first-generation Surinamese immigrants living in the Netherlands and their prevalence
suggestive of previous dengue virus infection, February 2008 - December 2011




Positive P% PR (95% CI) PR (95% CI)
n = 400 n = 325 81.3
Sex
male 148 119 80.4 1
female 252 206 81.7 1.0 (0.92-1.1)
Age (in years)
≤ 40 63 46 73.0 1 1
41-50 112 90 80.4 1.1 (0.92-1.2) 1.5 (0.79-3.0)
51-60 117 94 80.3 1.1 (0.92-1.3) 1.6 (0.84-3.2)
≥ 61 108 95 88.0 1.2 (1.0-1.4) 1.4 (0.74-2.9)
Duration lived in Suriname (in years)
≤ 15 79 43 54.4 1 1
16-20 112 88 78.6 1.4 (1.2-1.8) 1.4 (0.96-2.1)
21-25 90 82 91.1 1.7 (1.4-2.1) 1.6 (1.1-2.3)
≥ 26 115 108 93.9 1.7 (1.4-2.1) 1.7 (1.1-2.5)
History of yellow fever vaccination
no 258 211 81.8 1
yes (1 or 2) 142 114 80.3 0.98 (0.89-1.1)
Time between (most recent) yellow fever
vaccination and blood sample collection (in years)
≤ 5 41 29 70.7 1 1
> 5-10 41 35 85.4 1.2 (0.96-1.5) 1.2 (0.94-1.4)
> 10-15 41 36 87.8 1.2 (0.99-1.5) 1.2 (0.94-1.4)
> 15 10 6 60.0 0.85 (0.49-1.5) 0.79 (0.47-1.3)
Participants attended the Public Health Service’s Travel Clinic in Amsterdam for pre-travel advice.
P = prevalence.
PR = prevalence ratio.
* Variables that were significant at p < 0.1 were selected for inclusion in the multivariable model.
Overbosch et al. BMC Infectious Diseases 2014, 14:493 Page 3 of 5
http://www.biomedcentral.com/1471-2334/14/493
still unidentified. If we however hypothetically assume
that most of the DENV IgG positive participants had
only one previous DENV serotype infection, a high number
of Surinamese VFRs would be at risk for a secondary,
potentially more severe dengue. Especially, as before 1963
only DENV-2 American genotype was reported in the
Americas, but since then the region has been subject to re-
peated importation of new dengue serotypes and strains [7].
Over the last three decades a 4.6-fold increase in reported
cases was observed in the Americas and even an 8.3-fold
increase in DHF [15]. In the past ten years, all 4 dengue se-
rotypes have been circulating in Suriname [16,17].
The number of reported dengue cases or cases of severe
dengue among Surinamese VFRs in Suriname or after
return to the Netherlands, however, does not seem to be
as high as one would expect. In 2010, the Pan American
Health Organization (PAHO) reported only 113 clinical
cases of dengue in Suriname (all lab confirmed) of which
20 cases were severe dengue including one death [16]. It is
likely, though, that a substantial number of under- or
misdiagnosis occurs in Suriname as only lab-confirmed
dengue virus infections have been reported. Also, the
number of dengue cases or severe dengue infections in
the Netherlands is not clear as dengue is not a notifi-
able disease in this country. However, severe dengue is
extremely rare among Surinamese travelers returning
to the Netherlands who attend the Academic Medical
Center in Amsterdam, which serves an important
portion of Surinamese immigrants in the Netherlands
(in 2008, 338,000 Surinamese lived in the Netherlands of
whom 20% lived in Amsterdam) [18]. This low incidence
of severe dengue among Surinamese could possibly be
explained by host factors. Guzman’s review summarises
host factors that may reduce the risk of severe disease
during a second dengue virus infection, which include
race, second- or third-degree malnutrition, and poly-
morphisms in the Fcγ receptor and vitamin D receptor
genes [19]. Perhaps one or more of these factors can be
applied to the Surinamese population.
Our study has some other limitations. Cross-reactivity
between the dengue virus and other flaviviruses cannot
be excluded. However, in our study, cross-reactivity with
yellow fever vaccination is not likely since no relation
was found with either previous yellow fever vaccinations
or time between yellow fever vaccination and sample
collection. This is in agreement with the results of a
study on the incidence of dengue virus infection among
Dutch short-term travellers [4].
Second, the data used for this study is extracted from
a serum bank of travellers visiting the Public Health
Service’s Travel Clinic in Amsterdam. The serum bank
population may not be representative for the population
of first-generation Surinamese living in the Netherlands
and travelling to Suriname.
Third, data about duration lived in Suriname was self-
reported by the participants. In part, this was also the
case for history of yellow fever vaccination. Available
data concerning these variables could thus deviate from
the actual data, however, we do not consider these limi-
tations to have significantly affected our findings.
Lastly, frequency and duration of stays in endemic areas
after immigration was not incorporated as variables as
these data was missing in the serum bank. This could have
been of influence to the seroprevalence we found.
Conclusions
Most first-generation Surinamese immigrants living in
the Netherlands display evidence of past dengue virus
infection, probably comparable to Surinamese inhabitants.
Surinamese immigrants have possibly been infected
with fewer DENV serotypes, but whether this influences
the number of cases of (severe) dengue is unknown.
Incidence rates of severe dengue among Surinamese, a
seroprevalence study among Surinamese inhabitants
and serological tests which can discern the different
DENV serotypes should be performed to uncover im-
migrants as a potential risk group for (severe) dengue.
This could be of great importance for the development
of specific dengue preventive policies.
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